These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 24138602)

  • 1. Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia.
    Anzovino A; Lane DJ; Huang ML; Richardson DR
    Br J Pharmacol; 2014 Apr; 171(8):2174-90. PubMed ID: 24138602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia.
    Chiang S; Kovacevic Z; Sahni S; Lane DJ; Merlot AM; Kalinowski DS; Huang ML; Richardson DR
    Clin Sci (Lond); 2016 Jun; 130(11):853-70. PubMed ID: 27129098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia.
    Alfedi G; Luffarelli R; Condò I; Pedini G; Mannucci L; Massaro DS; Benini M; Toschi N; Alaimo G; Panarello L; Pacini L; Fortuni S; Serio D; Malisan F; Testi R; Rufini A
    Mov Disord; 2019 Mar; 34(3):323-334. PubMed ID: 30624801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione-dependent redox status of frataxin-deficient cells in a yeast model of Friedreich's ataxia.
    Auchère F; Santos R; Planamente S; Lesuisse E; Camadro JM
    Hum Mol Genet; 2008 Sep; 17(18):2790-802. PubMed ID: 18562474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of frataxin in fission yeast iron metabolism: implications for Friedreich's ataxia.
    Wang Y; Wang Y; Marcus S; Busenlehner LS
    Biochim Biophys Acta; 2014 Oct; 1840(10):3022-33. PubMed ID: 24997422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding a temporal dimension to the study of Friedreich's ataxia: the effect of frataxin overexpression in a human cell model.
    Vannocci T; Notario Manzano R; Beccalli O; Bettegazzi B; Grohovaz F; Cinque G; de Riso A; Quaroni L; Codazzi F; Pastore A
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29794127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal Stem Cell-Derived Factors Restore Function to Human Frataxin-Deficient Cells.
    Kemp K; Dey R; Cook A; Scolding N; Wilkins A
    Cerebellum; 2017 Aug; 16(4):840-851. PubMed ID: 28456899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Friedreich's ataxia.
    Alper G; Narayanan V
    Pediatr Neurol; 2003 May; 28(5):335-41. PubMed ID: 12878293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant.
    Huang ML; Becker EM; Whitnall M; Suryo Rahmanto Y; Ponka P; Richardson DR
    Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16381-6. PubMed ID: 19805308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Friedreich's ataxia: the vicious circle hypothesis revisited.
    Bayot A; Santos R; Camadro JM; Rustin P
    BMC Med; 2011 Oct; 9():112. PubMed ID: 21985033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Friedreich's ataxia: clinical features, pathogenesis and management.
    Cook A; Giunti P
    Br Med Bull; 2017 Dec; 124(1):19-30. PubMed ID: 29053830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches.
    Schmucker S; Puccio H
    Hum Mol Genet; 2010 Apr; 19(R1):R103-10. PubMed ID: 20413654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia.
    Becker E; Richardson DR
    Int J Biochem Cell Biol; 2001 Jan; 33(1):1-10. PubMed ID: 11167127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurodegeneration in Friedreich's ataxia: from defective frataxin to oxidative stress.
    Gomes CM; Santos R
    Oxid Med Cell Longev; 2013; 2013():487534. PubMed ID: 23936609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferroptosis as a Novel Therapeutic Target for Friedreich's Ataxia.
    Cotticelli MG; Xia S; Lin D; Lee T; Terrab L; Wipf P; Huryn DM; Wilson RB
    J Pharmacol Exp Ther; 2019 Apr; 369(1):47-54. PubMed ID: 30635474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich's ataxia.
    Khdour OM; Bandyopadhyay I; Chowdhury SR; Visavadiya NP; Hecht SM
    Bioorg Med Chem; 2018 Jul; 26(12):3359-3369. PubMed ID: 29773347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a structural understanding of Friedreich's ataxia: the solution structure of frataxin.
    Musco G; Stier G; Kolmerer B; Adinolfi S; Martin S; Frenkiel T; Gibson T; Pastore A
    Structure; 2000 Jul; 8(7):695-707. PubMed ID: 10903947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitochondrial dysfunction in the neuro-degenerative and cardio-degenerative disease, Friedreich's ataxia.
    Chiang S; Kalinowski DS; Jansson PJ; Richardson DR; Huang ML
    Neurochem Int; 2018 Jul; 117():35-48. PubMed ID: 28782591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
    Cooper JM; Schapira AH
    Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Prospects for Friedreich's Ataxia.
    Zhang S; Napierala M; Napierala JS
    Trends Pharmacol Sci; 2019 Apr; 40(4):229-233. PubMed ID: 30905359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.